Search Results - "Tobert, Jonathan"

LDL Cholesterol—How Low Can We Go? by Tobert, Jonathan A.

“…Combinations of lipid-lowering agents can often bring LDL cholesterol down to around 40 mg/dL (1 mmol/L). Randomized controlled trials indicate that this…”
Get full text

Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar by Preiss, David, Tobert, Jonathan A, Hovingh, G Kees, Reith, Christina

“…Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer…”
Get full text

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association by Newman, Connie B, Preiss, David, Tobert, Jonathan A, Jacobson, Terry A, Page, Robert L, Goldstein, Larry B, Chin, Clifford, Tannock, Lisa R, Miller, Michael, Raghuveer, Geetha, Duell, P Barton, Brinton, Eliot A, Pollak, Amy, Braun, Lynne T, Welty, Francine K

“…One in 4 Americans >40 years of age takes a statin to reduce the risk of myocardial infarction, ischemic stroke, and other complications of atherosclerotic…”
Get full text

Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol by Newman, Connie B, Tobert, Jonathan A

“…Abstract The discovery of PCSK9 and its role in regulating the low-density lipoprotein (LDL) receptor, and the effect of loss-of-function mutations of its…”
Get full text

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors by Tobert, Jonathan A

“…In the 1950s and 1960s, it became apparent that elevated concentrations of plasma cholesterol were a major risk factor for the development of coronary heart…”
Get full text

The nocebo effect in the context of statin intolerance by Tobert, Jonathan A., MD, PhD, Newman, Connie B., MD

“…Abstract The nocebo effect, the inverse of the placebo effect, is a well-established phenomenon that is under-appreciated in cardiovascular medicine. It refers…”
Get full text

Statins – Good drugs, not so good reputation by Tobert, Jonathan A.

Get full text

Statin Intolerance: Reconciling Clinical Trials and Clinical Experience by Newman, Connie B, Tobert, Jonathan A

Get full text

Statin tolerability: In defence of placebo-controlled trials by Tobert, Jonathan A, Newman, Connie B

“…Background Statin intolerance is a barrier to effective lipid-lowering treatment. A significant number of patients stop prescribed statins, or can take only a…”
Get full text

Management of Dyslipidemia for Cardiovascular Disease Risk Reduction by Tobert, Jonathan A, Newman, Connie B

Get full text

Now is good, earlier is better by Tobert, Jonathan A., Preiss, David

Get full text

Comment on the article by Moriarty et al by Newman, Connie B., MD, FACP, Tobert, Jonathan A., MD, PhD

Get full text

Simvastatin: a review by Pedersen, Terje R, Tobert, Jonathan A

“…Simvastatin is a long-established hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, first introduced in 1988. At the maximal recommended dose of…”
Get more information

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) by PEDERSEN, T. R, OLSSON, A. G, MIETTINEN, T, CHRISTOPHERSEN, B, TOBERT, J. A, MUSLINER, T. A, COOK, T. J, FAERGEMAN, O, KJEKSHUS, J, WEDEL, H, BERG, K, WILHELMSEN, L, HAGHFELT, T, THORGEIRSSON, G, PYÖRÄLÄ, K

“…The Scandinavian Simvastatin Survival Study (4S) randomized 4444 patients with coronary heart disease (CHD) and serum cholesterol 5.5 to 8.0 mmol/L (213 to 310…”
Get full text

Effect of Simvastatin on Ischemic Signs and Symptoms in the Scandinavian Simvastatin Survival Study (4S) by Pedersen, Terje R, Kjekshus, John, Pyörälä, Kalevi, Olsson, Anders G, Cook, Thomas J, Musliner, Thomas A, Tobert, Jonathan A, Haghfelt, Torben

“…In patients participating in the Scandinavian Simvastatin Survival Study, cholesterol lowering with simvastatin reduced the incidence of carotid bruits and…”
Get full text

Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I by Crouse, John R, Frohlich, Jiri, Ose, Leiv, Mercuri, Michele, Tobert, Jonathan A

“…A randomized, blinded, multicenter clinical trial was performed comparing low- and high-dose simvastatin (40 and 80 mg) with comparable doses of atorvastatin…”
Get full text

Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin by Gruer, Peter J.K, Vega, Jose M, Mercuri, Michele F, Dobrinska, Michael R, Tobert, Jonathan A

“…The long-term safety profile of simvastatin, established over 10 years of clinical use, is excellent. The principal adverse effect of all inhibitors of…”
Get full text

Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors by Preiss, David, Tobert, Jonathan A., Hovingh, G. Kees, Reith, Christina

“…Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer…”
Get full text

Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial by Lewin, Andrew J., Kipnes, Mark S., Meneghini, Luigi F., Plotkin, Diane J., Perevozskaya, Inna T., Shah, Sukrut, Maccubbin, Darbie L., Mitchel, Yale B., Tobert, Jonathan A.

“…Background: Coronary heart disease is the major cause of mortality in individuals with diabetes mellitus (DM). Given the increasingly aggressive low-density…”
Get full text

efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia by Hunninghake, D.B, Stein, E.A, Dujovne, C.A, Harris, W.S, Feldman, E.B, Miller, V.T, Tobert, J.A, Laskarzewski, P.M, Quiter, E, Held, J

“…Background. A diet low in saturated fat and cholesterol is the standard initial treatment for hypercholesterolemia. However, little quantitative information is…”
Get full text